The Zhitong Finance App learned that Insili Intelligence (03696) had an intraday high of more than 6%. As of press release, it had risen 4.87% to HK$52.75, with a turnover of HK$285 million.

According to the news, previously, Rentosertib, an experimental drug developed by Insilicon Intelligence to treat lung diseases, showed positive prospects in reversing biological markers of aging. Research shows that the biological age of patients can be reduced by up to 6 years through proteomics aging clock assessment. Currently, the drug has entered phase III clinical trials. Citi believes that Insilon Intelligence is still the first choice for the bank's artificial intelligence drug discovery (AIDD) sub-sector.

It is worth mentioning that recently, there has been intense catalysis in the field of AI pharmaceuticals. Kingsley Biotech announced a collaboration with Lilly TuneLab, an AI drug discovery platform, and Novo Nord also announced a partnership with Anthropic to accelerate the discovery of new drugs. China Merchants Securities pointed out that from the narrative of algorithms to pipeline value, the clinical implementation and commercialization of AI pharmaceuticals is about to explode.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.